Aethlon Medical, Inc. :AEMD-US: Earnings Analysis: 2017 By the Numbers : June 30, 2017

Aethlon Medical, Inc. reports financial results for the year ended March 31, 2017.


  • Change in operating cash flow of 19.02% compared to same period last year is about the same as change in earnings, likely no significant movement in accruals or reserves.
  • Narrowing of operating margins contributed to decline in earnings.

The table below shows the preliminary results and recent trends for key metrics such as revenues and net income growth:

2017 2016 2015 2014 2013
Relevant Numbers (Annual)
Revenues 0.39 0.89 0.76 1.62 1.23
Revenue Growth (YOY) N/A N/A N/A N/A N/A
Earnings -7.28 -4.87 -6.8 -13.36 -4.89
Earnings Growth (YOY) -49.34 28.32 49.11 -173.04 39.69
Net Margin -1855.81 -549.57 -891.53 -822.61 -397.73
EPS -0.94 -0.66 -1.22 -3.5 -1.5
Return on Equity -693.7 -452.45 N/A N/A N/A
Return on Assets -341.96 -249.24 -441.99 -1218.84 -732.68

Access our Ratings and Scores for Aethlon Medical, Inc.

Cash Versus Earnings – Sustainable Performance?

It is important to examine a company�s cash versus earnings numbers to gauge whether its performance is sustainable.

AEMD-US‘s year-on-year change in operating cash flow of 19.02% is around its change in earnings. This suggests that there are likely no significant movement in accruals or reserves for managing earnings this period.


The company’s decline in earnings has been influenced by the following factors: (1) Decline in operating margins (EBIT margins) from -494.58% to -1,555.41% and (2) one-time items that contributed to a decrease in pretax margins from -559.30% to -1,863.61%

EBIT Margin History
PreTax Margin History

Access our Ratings and Scores for Aethlon Medical, Inc.

Company Profile

Aethlon Medical, Inc. is a medical device company, which focuses on creating devices for the treatment of cancer, infectious diseases, and other life-threatening conditions. It develops Aethlon Hemopurifier, a medical device that targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The company was founded by James A. Joyce in May 1998 and is headquartered in San Diego, CA.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of AEMD-US.